Skip to main content
SpringerLink
Log in

JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia

  • Original Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Background: JAK2V617F mutation occurs in 90% of polycythemia vera (PV) and in 50% of essential thrombocythemia (ET) patients. Materials and methods: 253 consecutive patients affected by myeloproliferative disorders (MPD, 121 PV, 132 ET) were evaluated and stratified in 4 age groups: 18–39, 40–59, 60–75 and over 75 years (>75). The JAK2V617F mutation was searched and its allele burden was evaluated. Results: The percentage of mutated patients increased progressively with age mainly in patients >75 (p=0.0015 vs 18–39, p=0.0021 vs 40–59 and p=0.012 vs 60–75). We also found a progressive increase in allele burden with age (R2=0.042). Thrombotic events were more common in patients carrying the mutation in comparison with wild type (WT) (p=0.006, coefficient risk 1.94). No differences in the percentage of patients carrying the JAK2V617F mutation were found, in spite of different follow-up durations (<5 yrs, 5–10 yrs, 10–15 yrs, >15 yrs). The JAK2V617F allele burden was similar in patients with (57±31%) and without (45±26%) long-term hydroxyurea treatment. Conclusions: JAK2V617F mutation is more common in old than in young patients with MPD. Older patients have an higher allele burden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem cell and probable clonal origin of the disease. N Engl J Med 1976; 295: 913–6.

    Article  CAS  PubMed  Google Scholar 

  2. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58: 916–8.

    CAS  PubMed  Google Scholar 

  3. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–97.

    Article  CAS  PubMed  Google Scholar 

  4. Baxter EJ, Scott LM, Campbell PJ et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–61.

    CAS  PubMed  Google Scholar 

  5. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation in JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–90.

    Article  CAS  PubMed  Google Scholar 

  6. James C, Ugo V, Le Couedec JP et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144–8.

    Article  CAS  PubMed  Google Scholar 

  7. Zhao R, Xing S, Li Z et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Campbell P, Scott LM, Buck G et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2V617F mutation status: a prospective study. Lancet 2005; 366: 1945–53.

    Article  CAS  PubMed  Google Scholar 

  10. Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556–62.

    CAS  PubMed  Google Scholar 

  11. Finazzi G, Rambaldi A, Guerini V, Carobbio A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–6.

    Article  PubMed  Google Scholar 

  12. Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera and essential thrombocythemia. Blood 2007; 110: 840–6.

    Article  CAS  PubMed  Google Scholar 

  13. Lansdorp PM. Telomers, stem cells and hematology. Blood 2008; 111: 1759–66.

    Article  CAS  PubMed  Google Scholar 

  14. Alzarez-Larran A, Cervantes F, Bellosillo B et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218–23.

    Article  Google Scholar 

  15. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocytemia treated with busulphan and hydroxyurea: long-term follow-up of a randomised clinical trial. Br J Haematol 2000; 110: 577–83.

    Article  CAS  PubMed  Google Scholar 

  16. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic bcr/abl-negative myeloproliferative disorders. Leukemia 2008; 22: 905–14.

    Article  CAS  PubMed  Google Scholar 

  17. Berlin N. Diagnosis and classification of polycythemias. Semin Hematol 1978; 12: 339–51.

    Google Scholar 

  18. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39.

    CAS  PubMed  Google Scholar 

  19. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 292–302.

    Article  Google Scholar 

  20. Passamonti F, Rumi E, Pietra D et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34 cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676–82.

    Article  CAS  PubMed  Google Scholar 

  21. Lussana F, Cabrelon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Associations of V167FJak2 mutation with the risk of thrombosis among patients with essential thrombocythemia or idiopathic myelofibrosis: a systemic review. Thromb Res 2009; 124: 409–17.

    Article  CAS  PubMed  Google Scholar 

  22. Antonioli E; Guglielmelli P, Pancrazi A et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–9.

    Article  CAS  PubMed  Google Scholar 

  23. Teofili L, Giona F, Martini M et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007; 110: 3384–6.

    Article  CAS  PubMed  Google Scholar 

  24. Tefferi A, Thiele J, Orazi A et al. Proposal and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–7.

    Article  CAS  PubMed  Google Scholar 

  25. Lippert E, Boissinot M, Kralovics R et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865–7.

    Article  CAS  PubMed  Google Scholar 

  26. Beer PA, Campbell PJ, Scott LM et al. MPL mutation in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141–9.

    Article  CAS  PubMed  Google Scholar 

  27. Girodon F, Schaeffer C, Cleyrat C et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V671Fpositive patients within the first years of hydroxyurea therapy. Haematologica 2008; 93: 1723–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine CLOPD, Department of Medical and Surgical Sciences, University of Padova Medical School, via Giustiniani 2, 35128, Padova, Italy

    Maria Luigia Randi, Elisabetta Ruzzon, Fabiana Tezza, Margherita Scapin, Elena Duner, Raffaella Scandellari & Fabrizio Fabris

Authors
  1. Maria Luigia Randi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabetta Ruzzon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabiana Tezza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Margherita Scapin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena Duner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raffaella Scandellari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fabrizio Fabris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Luigia Randi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Randi, M.L., Ruzzon, E., Tezza, F. et al. JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia. Aging Clin Exp Res 23, 17–21 (2011). https://doi.org/10.1007/BF03324948

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03324948

Search

Navigation